154325-75-4

Basic information

• Product Name: ETHYL 5-BROMO-2,2-DIMETHYL-4-OXOPENTANOATE
• Synonyms: ETHYL 5-BROMO-2,2-DIMETHYL-4-OXOPENTANOATE;5-Bromo-2,2-dimethyl-4-oxopentanoic Acid Ethyl Ester;Ethyl 5-Bromo-2,2-dimethyl-4-oxopentanoate Ethyl 5-Chloro-2,2-dimethyl-4-oxopentanoate (Bromo/Chloro Mixture);(Mixture of BroMo/Chloro);5-Chloro-2,2-diMethyl-4-oxopentanoic Acid Ethyl Ester;Pentanoic acid, 5-broMo-2,2-diMethyl-4-oxo-, ethyl ester
• CAS NO: 154325-75-4
• Molecular Formula: C9H15BrO3
• Molecular Weight: 251.12
• Product Categories: All Aliphatics;Aliphatics;Inhibitors;Miscellaneous Reagents;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 154325-75-4.mol

Chemical Properties

• Boiling Point: 290℃
• Flash Point: 129℃
• Appearance: Colourless Oil
• Density: 1.315
• Vapor Pressure: 0.0021mmHg at 25°C
• Refractive Index: 1.469
• Storage Temp.: Refrigerator
• Solubility: Chloroform, Ethyl Acetate
• CAS DataBase Reference: ETHYL 5-BROMO-2,2-DIMETHYL-4-OXOPENTANOATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 5-BROMO-2,2-DIMETHYL-4-OXOPENTANOATE(154325-75-4)
• EPA Substance Registry System: ETHYL 5-BROMO-2,2-DIMETHYL-4-OXOPENTANOATE(154325-75-4)

Safety Data

• Hazardous Substances Data: 154325-75-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
ETHYL 5-BROMO-2,2-DIMETHYL-4-OXOPENTANOATE is used as a leukotriene biosynthesis inhibitor for its ability to modulate the production of leukotrienes, which are inflammatory mediators involved in various diseases such as asthma and inflammatory bowel disease. By inhibiting leukotriene biosynthesis, ETHYL 5-BROMO-2,2-DIMETHYL-4-OXOPENTANOATE can potentially alleviate symptoms and improve the quality of life for patients suffering from these conditions.
Used in Biochemical Research:
In the field of biochemical research, ETHYL 5-BROMO-2,2-DIMETHYL-4-OXOPENTANOATE serves as an essential intermediate for the synthesis of various indolylalkanoate derivatives. These derivatives can be further studied for their potential therapeutic applications and to gain a deeper understanding of the underlying mechanisms of leukotriene biosynthesis and its role in disease processes.
Used in Drug Development:
ETHYL 5-BROMO-2,2-DIMETHYL-4-OXOPENTANOATE is also utilized in drug development as a key building block for the creation of novel therapeutic agents targeting leukotriene biosynthesis. Its unique chemical structure allows for the design and synthesis of new drugs with improved efficacy, selectivity, and safety profiles, ultimately contributing to the advancement of treatment options for various inflammatory and allergic disorders.

InChI:InChI=1/C9H15BrO3/c1-4-13-8(12)9(2,3)5-7(11)6-10/h4-6H2,1-3H3

Upstream product

• 118427-36-4 ethyl 4-chloro-2,2-dimethyl-4-pentenoate 
• 97-62-1 Ethyl isobutyrate 

Downstream Products

• 136558-13-9 ethyl 5-t-butylthio-2,2-dimethyl-4-oxo-pentanoate 

Relevant articles and documents

COMPOUNDS AND METHODS FOR TREATMENT OF HEDGEHOG PATHWAY ASSOCIATED CONDITIONS

Provided herein is novel compounds of formula (I), (II), (III), (IV), and (V) as described in the specification, and pharmaceutically acceptable salts, solvates, and prodrugs and compositions thereof, and methods of measuring hedgehog pathway activation in tumor cells, examining tumor cell proliferation, differentiation and apoptosis and using the compounds and pharmaceutical compositions disclosed for treatment of diseases and disorders associated with the hedgehog signaling pathway.

DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES

The application describes dihydropyrimidine derivatives which are useful in the treatment or prevention of HBV infection or of HBV-induced diseases, more particularly of HBV chronic infection or of diseases induced by HBV chronic infection, as well as pharmaceutical or medical applications thereof.

A hedgehog pathway inhibitor and its preparation method and application

The invention relates to a compound, the structural formula of the compound is shown as formula (1) is shown. The invention also provides a method for preparing the compound. The invention also provides the above-mentioned compound or its pharmaceutically

New-type compound and preparation method and application thereof

The invention relates to a new-type compound. A structural formula of the new-type compound is as shown in a formula (1). The invention further provides a method for preparing the above new-type compound. The invention further provides an application of the above new-type compound or pharmaceutically acceptable salt thereof, a solvate or a drug compound for preparing a drug for treating a diseaserelated to activation of a hedgehog passage. The provided above new-type compound can be used for preparing the drug for treating the disease related to the activation of the hedgehog passage. The new-type compound is particularly capable of inhibiting growth of medulloblastoma well, and can be used for preparing a drug for treating medulloblastoma related diseases.

Compound as well as preparation method and application thereof

The invention relates to a compound. The structural formula of the compound is shown as formula (1) in the description, wherein R is H or CH3. The invention further provides a preparation method of the compound and an application of the compound or pharmaceutically acceptable salt, solvate or drug complex of the compound to preparation of drugs for treating hedgehog pathway activation-related diseases. The compound can be used for preparing the drugs for treating the hedgehog pathway activation-related diseases, can well inhibit medulloblastoma growth and can be used for preparing drugs for treating medulloblastoma-related diseases.

5-Lipoxygenase-Activating Protein Inhibitor

Described herein is the FLAP inhibitor 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxy-pyridin-3-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of p

5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITOR

Described herein are methods for the synthesis of 3-[5-(pyridin-2-ylmethoxy)-3-(2-methyl-2-propylthio)-1-[4-(2-methoxypyridin-5-yl)benzyl]-indol-2-yl]-2,2-dimethyl-propionic acid, pharmaceutically acceptable salts, pharmaceutically acceptable solvates the